MorphoSys AG — Earnings Release 2001

May 28, 2001

News Details

Ad-hoc | 28 May 2001 07:56

MorphoSys AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorhoSys Posts First Quarter Results 2001 Martinsried/Munich, — May 28, 2001 — MorphoSys AG (Neuer Markt Mor) achieved revenues amounting to EUR 2.76 million in the first quarter of 2001, representing an increase of 97 percent compared to the same period of the previous year. Total operating expense for Ql 2000 amounted to EUR 4.99 million, an increase of 74 percent, or EUR 2.13 million, compared to the year 2000. The Company’s net loss for the first quarter of 2001 amounted to a total of EUR -2.03 million and a net loss per share of -0.57 Euros, representing an improvement of 55.4 percent and 56.4 percent, respectively, in comparison with the previous year. Highlights of the first quarter included: Achievement of a first milestone in our therapeutic antibody collaboration with Bayer – the generation of a high affinity HuCAL(R) antibody against a Bayer target. Exercise of an option to develop a second therapeutic antibody with Bayer. Attainment of a second milestone in the collaboration with Hoffmann-La Roche for the development of an antibody against Alzheimer’s Disease. Recruitment of two senior Corporate Development executives in the USA. end of ad hoc announcement (c) DGAP 28.05.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 280756 Mai 01